methane has been researched along with Colitis Gravis in 8 studies
Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed)
methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Since there are two gases (hydrogen and methane) measured on lactulose breath testing, we evaluated whether the different gas patterns on lactulose breath testing coincide with diarrhea and constipation symptoms in IBS and IBD." | 3.72 | Methane production during lactulose breath test is associated with gastrointestinal disease presentation. ( Chow, EJ; Hasan, A; Kong, Y; Mayer, AG; Park, S; Pimentel, M, 2003) |
| "Methane is an inert gas and has probably no direct effect in man." | 2.39 | [Hydrogen metabolism in the large intestine--physiology and clinical implications]. ( Christl, SU; Kasper, H; Scheppach, W, 1995) |
| "Fecal samples from 25 subjects with ulcerative colitis and 17 controls were incubated in 4-L containers, and gas release was assessed at intervals over 24 h." | 1.30 | Fecal hydrogen sulfide production in ulcerative colitis. ( Ellis, CJ; Furne, JK; Levine, J; Levitt, MD; Springfield, J, 1998) |
| "Patients with Crohn's disease, ulcerative colitis, and pneumatosis cystoides intestinalis had significantly lower prevalences of methane excretion (13%, 15%, and 11% respectively)." | 1.27 | Methane excretion in man--a study of breath, flatus, and faeces. ( Brydon, WG; Eastwood, MA; McKay, LF, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, S | 1 |
| Han, M | 1 |
| Liu, S | 1 |
| Fan, L | 1 |
| Shi, H | 1 |
| Li, P | 1 |
| Karpińska, G | 1 |
| Dobrowolski, JC | 1 |
| Yinda, CK | 1 |
| Rector, A | 1 |
| Zeller, M | 1 |
| Conceição-Neto, N | 1 |
| Heylen, E | 1 |
| Maes, P | 1 |
| Ghogomu, SM | 1 |
| Van Ranst, M | 1 |
| Matthijnssens, J | 1 |
| Arthanari, SK | 1 |
| Vanitha, J | 1 |
| Ganesh, M | 1 |
| Venkateshwaran, K | 1 |
| de Lama Caro-Patón, G | 1 |
| García-Salido, A | 1 |
| Iglesias-Bouzas, MI | 1 |
| Guillén, M | 1 |
| Cañedo-Villaroya, E | 1 |
| Martínez-Romera, I | 1 |
| Serrano-González, A | 1 |
| Casado-Flores, J | 1 |
| Gale, P | 2 |
| Chen, X | 2 |
| Li, H | 1 |
| Lucero-Prisno, DE | 1 |
| Abdullah, AS | 1 |
| Huang, J | 1 |
| Laurence, C | 1 |
| Liang, X | 1 |
| Ma, Z | 1 |
| Mao, Z | 1 |
| Ren, R | 1 |
| Wu, S | 1 |
| Wang, N | 1 |
| Wang, P | 2 |
| Wang, T | 1 |
| Yan, H | 1 |
| Zou, Y | 1 |
| Olsen, KM | 1 |
| Gabler, NK | 1 |
| Rademacher, CJ | 1 |
| Schwartz, KJ | 1 |
| Schweer, WP | 1 |
| Gourley, GG | 1 |
| Patience, JF | 1 |
| Rauch, JC | 1 |
| Stokes, RS | 1 |
| Shike, DW | 1 |
| Luebbe, KM | 1 |
| Stalker, LA | 1 |
| Klopfenstein, TJ | 1 |
| Funston, RN | 1 |
| Unger, PA | 1 |
| Lighaam, LC | 1 |
| Vermeulen, E | 1 |
| Kruithof, S | 1 |
| Makuch, M | 1 |
| Culver, EL | 1 |
| van Bruggen, R | 1 |
| Remmerswaal, EBM | 1 |
| Ten Berge, IJM | 1 |
| Emmens, RW | 1 |
| Niessen, HWM | 1 |
| Barnes, E | 1 |
| Wolbink, GJ | 1 |
| van Ham, SM | 1 |
| Rispens, T | 1 |
| Liang, JX | 1 |
| Lin, J | 1 |
| Liu, J | 1 |
| Wang, X | 1 |
| Zhang, T | 1 |
| Li, J | 1 |
| Wu, Y | 2 |
| Venier, M | 1 |
| Salamova, A | 1 |
| Gonçales, VR | 1 |
| Lian, J | 1 |
| Gautam, S | 1 |
| Tilley, RD | 1 |
| Gooding, JJ | 1 |
| Kandel, YR | 1 |
| Bradley, CA | 1 |
| Chilvers, MI | 1 |
| Mathew, FM | 1 |
| Tenuta, AU | 1 |
| Smith, DL | 1 |
| Wise, KA | 1 |
| Mueller, DS | 1 |
| Lu, N | 1 |
| Lu, M | 1 |
| Liu, P | 1 |
| Xu, H | 1 |
| Qiu, X | 1 |
| Hu, S | 1 |
| Bai, S | 1 |
| Wu, J | 1 |
| Xue, S | 1 |
| Dai, X | 1 |
| Dharmage, SC | 1 |
| Abramson, MJ | 1 |
| Erbas, B | 1 |
| Bennett, CM | 1 |
| Svanes, C | 1 |
| Hui, J | 1 |
| Axelrad, C | 1 |
| Lowe, AJ | 1 |
| Lodge, CJ | 1 |
| Hoshi, M | 1 |
| Osawa, Y | 1 |
| Nakamoto, K | 1 |
| Morita, N | 1 |
| Yamamoto, Y | 1 |
| Ando, T | 1 |
| Tashita, C | 1 |
| Nabeshima, T | 1 |
| Saito, K | 1 |
| Gianesello, L | 1 |
| Del Prete, D | 1 |
| Ceol, M | 1 |
| Priante, G | 1 |
| Calò, LA | 1 |
| Anglani, F | 1 |
| Vekaria, HJ | 1 |
| Hubbard, WB | 1 |
| Scholpa, NE | 1 |
| Spry, ML | 1 |
| Gooch, JL | 1 |
| Prince, SJ | 1 |
| Schnellmann, RG | 1 |
| Sullivan, PG | 1 |
| Zhang, Q | 1 |
| Hu, R | 1 |
| Gu, Z | 1 |
| Zhang, M | 1 |
| Zhang, Z | 1 |
| Peng, Y | 1 |
| Feng, L | 1 |
| Li, X | 3 |
| Zhao, C | 1 |
| Sarfaraz, K | 1 |
| Gao, L | 1 |
| Wang, H | 1 |
| Wan, C | 1 |
| Leng, J | 1 |
| Yang, P | 1 |
| Gao, X | 1 |
| Gao, J | 1 |
| Emam, HE | 1 |
| Saad, NM | 1 |
| Abdallah, AEM | 1 |
| Ahmed, HB | 1 |
| Palombo, M | 1 |
| Ianus, A | 1 |
| Guerreri, M | 1 |
| Nunes, D | 1 |
| Alexander, DC | 1 |
| Shemesh, N | 1 |
| Zhang, H | 1 |
| Xiong, Q | 1 |
| Liu, YS | 1 |
| Hu, LX | 1 |
| Shi, ZQ | 1 |
| Ying, GG | 1 |
| Chen, R | 1 |
| Hong, X | 1 |
| Yan, S | 1 |
| Zha, J | 1 |
| Gu, H | 1 |
| Zhong, Q | 1 |
| Zeng, Y | 1 |
| Zhang, S | 1 |
| Bu, Y | 1 |
| Farghali, M | 1 |
| Mayumi, M | 1 |
| Syo, K | 1 |
| Satoshi, A | 1 |
| Seiichi, Y | 1 |
| Takashima, S | 1 |
| Ono, H | 1 |
| Ap, Y | 1 |
| Yamashiro, T | 1 |
| Ahmed, MM | 1 |
| Kotb, S | 1 |
| Iwasaki, M | 1 |
| Ihara, I | 1 |
| Umetsu, K | 1 |
| Hu, B | 1 |
| Wang, Y | 2 |
| Quan, J | 1 |
| Huang, K | 1 |
| Gu, X | 1 |
| Zhu, J | 1 |
| Yan, Y | 1 |
| Wu, P | 1 |
| Yang, L | 1 |
| Zhao, J | 1 |
| Koók, L | 1 |
| Nemestóthy, N | 1 |
| Bélafi-Bakó, K | 1 |
| Bakonyi, P | 1 |
| Luo, X | 1 |
| Zhang, F | 1 |
| Li, Q | 1 |
| Xia, Q | 1 |
| Li, Z | 1 |
| Ye, W | 1 |
| Li, S | 1 |
| Ge, C | 1 |
| Zakkula, A | 1 |
| Pulipati, S | 1 |
| Dittakavi, S | 1 |
| Bestha, RM | 1 |
| Zainuddin, M | 1 |
| Trivedi, RK | 1 |
| Mullangi, R | 1 |
| Lo, GH | 1 |
| Lin, CW | 1 |
| Tai, CM | 1 |
| Perng, DS | 1 |
| Chen, IL | 1 |
| Yeh, JH | 1 |
| Lin, HC | 1 |
| Rocha, GS | 1 |
| Silva, MKL | 1 |
| Cesarino, I | 1 |
| Hazzaa, SM | 1 |
| Abdelaziz, SAM | 1 |
| Abd Eldaim, MA | 1 |
| Abdel-Daim, MM | 1 |
| Elgarawany, GE | 1 |
| Larsson, P | 1 |
| Ljuslinder, I | 1 |
| Öhlund, D | 1 |
| Myte, R | 1 |
| Löfgren-Burström, A | 1 |
| Zingmark, C | 1 |
| Ling, A | 1 |
| Edin, S | 1 |
| Palmqvist, R | 1 |
| Murthi, P | 1 |
| Rajaraman, G | 1 |
| Erwich, JJHM | 1 |
| Dimitriadis, E | 1 |
| Yoon, HG | 1 |
| Oh, D | 1 |
| Ahn, YC | 1 |
| Noh, JM | 1 |
| Pyo, H | 1 |
| Cho, WK | 1 |
| Song, YM | 1 |
| Park, M | 1 |
| Hwang, NY | 1 |
| Sun, JM | 1 |
| Kim, HK | 1 |
| Zo, JI | 1 |
| Shim, YM | 1 |
| Persano, A | 1 |
| Quaranta, F | 1 |
| Taurino, A | 1 |
| Siciliano, PA | 1 |
| Iannacci, J | 1 |
| Malekbala, MR | 1 |
| Soltani, S | 1 |
| Abdul Rashid, S | 1 |
| Abdullah, LC | 1 |
| Rashid, U | 1 |
| Nehdi, IA | 1 |
| Choong, TSY | 1 |
| Teo, SH | 1 |
| Xu, P | 1 |
| Yan, F | 1 |
| Zhao, Y | 1 |
| Sun, S | 1 |
| Ying, L | 1 |
| Quinzi, V | 1 |
| Caruso, S | 1 |
| Mummolo, S | 1 |
| Nota, A | 1 |
| Angelone, AM | 1 |
| Mattei, A | 1 |
| Gatto, R | 1 |
| Marzo, G | 1 |
| Xin, W | 1 |
| Severino, J | 1 |
| Venkert, A | 1 |
| Yu, H | 1 |
| Knorr, D | 1 |
| Yang, JM | 1 |
| Carlson, L | 1 |
| Hicks, R | 1 |
| De Rosa, I | 1 |
| Beckmann, NA | 1 |
| Bitsch, RG | 1 |
| Schonhoff, M | 1 |
| Siebenrock, KA | 1 |
| Schwarze, M | 1 |
| Jaeger, S | 1 |
| Pimentel, M | 1 |
| Mayer, AG | 1 |
| Park, S | 1 |
| Chow, EJ | 1 |
| Hasan, A | 1 |
| Kong, Y | 1 |
| Piqué, JM | 1 |
| Pallarés, M | 1 |
| Cusó, E | 1 |
| Vilar-Bonet, J | 1 |
| Gassull, MA | 1 |
| Christl, SU | 1 |
| Scheppach, W | 1 |
| Kasper, H | 1 |
| Levine, J | 2 |
| Furne, JK | 2 |
| Levitt, MD | 2 |
| Ellis, CJ | 1 |
| Springfield, J | 1 |
| McKay, LF | 1 |
| Eastwood, MA | 1 |
| Brydon, WG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Efficacy and Safety of Single, Daily Oral Doses of SYN-010 Compared to Placebo in Adult Patients With Irritable Bowel Syndrome With Constipation (EASE-DO)[NCT03763175] | Phase 2 | 59 participants (Actual) | Interventional | 2018-12-24 | Terminated (stopped due to Interim Futility Analysis) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in exhaled methane level as a potential predictor of constipation improvement will be evaluated by comparing single-point breath tests pre- and post-treatment. (NCT03763175)
Timeframe: After completing course of SYN-010
| Intervention | particles per million (Mean) |
|---|---|
| SYN-010 21 mg | -22.623 |
| SYN-010 42 mg | -4.785 |
| Placebo | -10.081 |
Subjects will record their daily bowel movements throughout the duration of the study. Change in weekly average number of CSBMs will be evaluated by comparing reported values pre- and post-treatment. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Weekly average CSBMs (Least Squares Mean) |
|---|---|
| SYN-010 21 mg | 1.53 |
| SYN-010 42 mg | 0.32 |
| Placebo | 0.51 |
Change in exhaled methane level as a potential predictor of constipation improvement will be evaluated by comparing lactulose breath tests pre- and post-treatment. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | particles per million * min (Mean) |
|---|---|
| SYN-010 21 mg | -18.678 |
| SYN-010 42 mg | -20.137 |
| Placebo | -39.199 |
An overall abdominal pain intensity responder is defined as a patient with a weekly abdominal pain intensity response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly response abdominal pain intensity response is defined as a decrease in the patient's weekly average score for worst abdominal pain in the past 24 hours of at least 30% compared to baseline, with stool frequency unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 4 |
| SYN-010 42 mg | 4 |
| Placebo | 7 |
An overall bloating responder is defined as a patient with a weekly bloating response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly bloating response is defined as a weekly average bloating score of at least 30% improvement compared to baseline, with stool frequency unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 3 |
| SYN-010 42 mg | 3 |
| Placebo | 1 |
An overall 12-week responder is defined as a patient with a weekly response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly response is defined as a decrease in the patient's weekly average score for worst abdominal pain in the past 24 hours of at least 30% compared to baseline and a stool frequency increase of 1 or more CSBMs per week compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 1 |
| SYN-010 42 mg | 2 |
| Placebo | 6 |
An overall stool frequency responder is defined as a patient with a weekly stool frequency response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly stool frequency response is defined as a stool frequency increase of 1 or more CSBMs per week compared with baseline, with abdominal pain unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 4 |
| SYN-010 42 mg | 6 |
| Placebo | 9 |
Subjects will record their use of rescue medication throughout the study period. Proportion of patients using rescue medication after completing the 12-week course of treatment will be compared to those reporting usage at baseline screening period. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 9 |
| SYN-010 42 mg | 11 |
| Placebo | 8 |
Outcome will be assessed by evaluating proportion of patients reporting adequate relief pre- and post-treatment on validated questionnaire. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 1 |
| SYN-010 42 mg | 2 |
| Placebo | 6 |
2 reviews available for methane and Colitis Gravis
| Article | Year |
|---|---|
Topics: Acetaminophen; Administration, Oral; Adolescent; Adsorption; Adult; Allyl Compounds; Amylopectin; Am | 2013 |
[Hydrogen metabolism in the large intestine--physiology and clinical implications].
Topics: Colitis, Ulcerative; Colon; Colonic Neoplasms; Fermentation; Flatulence; Gases; Humans; Hydrogen; Me | 1995 |
1 trial available for methane and Colitis Gravis
| Article | Year |
|---|---|
Topics: Acetaminophen; Administration, Oral; Adolescent; Adsorption; Adult; Allyl Compounds; Amylopectin; Am | 2013 |
6 other studies available for methane and Colitis Gravis
| Article | Year |
|---|---|
Composition and diverse differences of intestinal microbiota in ulcerative colitis patients.
Topics: Butyrates; Clostridiales; Colitis, Ulcerative; Gastrointestinal Microbiome; Humans; Lactams, Macrocy | 2022 |
Methane production during lactulose breath test is associated with gastrointestinal disease presentation.
Topics: Breath Tests; Colitis, Ulcerative; Constipation; Crohn Disease; Databases, Factual; Gastrointestinal | 2003 |
Methane production and colon cancer.
Topics: Adolescent; Adult; Aged; Breath Tests; Child; Colitis, Ulcerative; Colonic Neoplasms; Colonic Polyps | 1984 |
Ashkenazi Jews, sulfur gases, and ulcerative colitis.
Topics: Adolescent; Adult; Aged; Breath Tests; Colitis, Ulcerative; Colon; Humans; Hydrogen Sulfide; Jews; M | 1996 |
Fecal hydrogen sulfide production in ulcerative colitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacteria; Carbon Dioxide; Carbon Monoxide; Chromatograph | 1998 |
Methane excretion in man--a study of breath, flatus, and faeces.
Topics: Adolescent; Adult; Aged; Breath Tests; Colitis, Ulcerative; Colon; Crohn Disease; Feces; Female; Gas | 1985 |